Suppr超能文献

FSH 受体基因型不能预测 ICSI 患者的中期-II 卵母细胞产量或受精率。

FSH receptor genotype does not predict metaphase-II oocyte output or fertilization rates in ICSI patients.

机构信息

Department of Reproductive Medicine, St. Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.

出版信息

Reprod Biomed Online. 2013 Sep;27(3):305-9. doi: 10.1016/j.rbmo.2013.06.005. Epub 2013 Jun 20.

Abstract

The objective of this study was to assess the role of the variant p.Asn680Ser in the FSH receptor gene (FSHR) in determining oocyte maturity. It also assessed the relationship between this FSHR variant with metaphase-II oocyte output rate (MOR) and the fertilization rate. This was a prospective observational study based at a tertiary referral centre for reproductive medicine. Women (n=212) undergoing their first cycle of ovarian stimulation for IVF with intracytoplasmic sperm injection (ICSI) were included in the study. Baseline pelvic ultrasound and blood tests were taken on day 2 or 3 of the cycle for assessment of baseline hormones and for DNA extraction. Genotypes for FSHR p.Asn680Ser was determined using TaqMan allelic discrimination assay. The outcome measures were the total dose of exogenous gonadotrophins used, antral follicle count (AFC), number of mature (metaphase-II) oocytes retrieved, MOR and fertilization rate. No statistically significant differences were found between the number of mature oocytes retrieved, MOR or fertilization rates among the patients with different p.Asn680Ser FSHR genotypes. No significant difference was noted in the clinical pregnancy rates per transfer. There is no evidence that the p.Asn680Ser FSHR genotype predicts oocyte maturity.

摘要

本研究旨在评估 FSH 受体基因(FSHR)中变体 p.Asn680Ser 在决定卵母细胞成熟度中的作用。还评估了这种 FSHR 变体与中期 II 卵母细胞输出率(MOR)和受精率之间的关系。这是一项在生殖医学三级转诊中心进行的前瞻性观察研究。纳入了 212 名接受体外受精(IVF)-胞浆内精子注射(ICSI)的首次卵巢刺激周期的女性。在周期的第 2 或第 3 天进行基线盆腔超声和血液检查,以评估基线激素水平并提取 DNA。使用 TaqMan 等位基因鉴别测定法确定 FSHR p.Asn680Ser 的基因型。主要观察指标为使用的外源性促性腺激素总剂量、窦卵泡计数(AFC)、可获得的成熟(中期 II)卵母细胞数量、MOR 和受精率。不同 p.Asn680Ser FSHR 基因型患者的成熟卵母细胞数量、MOR 或受精率之间无统计学差异。每个移植周期的临床妊娠率无显著差异。没有证据表明 p.Asn680Ser FSHR 基因型可以预测卵母细胞成熟度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验